Apollo Medical Holdings, Inc. (NASDAQ:AMEH) Earns A Nice Return On Capital Employed

Today we’ll evaluate Apollo Medical Holdings, Inc. (NASDAQ:AMEH) to determine whether it could have potential as an investment idea. To be precise, we’ll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business.

First up, we’ll look at what ROCE is and how we calculate it. Second, we’ll look at its ROCE compared to similar companies. And finally, we’ll look at how its current liabilities are impacting its ROCE.

Understanding Return On Capital Employed (ROCE)

ROCE is a measure of a company’s yearly pre-tax profit (its return), relative to the capital employed in the business. In general, businesses with a higher ROCE are usually better quality. Ultimately, it is a useful but imperfect metric. Renowned investment researcher Michael Mauboussin has suggested that a high ROCE can indicate that ‘one dollar invested in the company generates value of more than one dollar’.

How Do You Calculate Return On Capital Employed?

The formula for calculating the return on capital employed is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets – Current Liabilities)

Or for Apollo Medical Holdings:

0.18 = US$38m ÷ (US$552m – US$92m) (Based on the trailing twelve months to September 2018.)

So, Apollo Medical Holdings has an ROCE of 18%.

See our latest analysis for Apollo Medical Holdings

Want to help shape the future of investing tools and platforms? Take the survey and be part of one of the most advanced studies of stock market investors to date.

Does Apollo Medical Holdings Have A Good ROCE?

One way to assess ROCE is to compare similar companies. Apollo Medical Holdings’s ROCE appears to be substantially greater than the 13% average in the Healthcare industry. We consider this a positive sign, because it suggests it uses capital more efficiently than similar companies. Independently of how Apollo Medical Holdings compares to its industry, its ROCE in absolute terms appears decent, and the company may be worthy of closer investigation.

In our analysis, Apollo Medical Holdings’s ROCE appears to be 18%, compared to 3 years ago, when its ROCE was 11%. This makes us think the business might be improving.

NasdaqCM:AMEH Last Perf January 16th 19
NasdaqCM:AMEH Last Perf January 16th 19

When considering ROCE, bear in mind that it reflects the past and does not necessarily predict the future. ROCE can be misleading for companies in cyclical industries, with returns looking impressive during the boom times, but very weak during the busts. ROCE is only a point-in-time measure. What happens in the future is pretty important for investors, so we have prepared a free report on analyst forecasts for Apollo Medical Holdings.

Do Apollo Medical Holdings’s Current Liabilities Skew Its ROCE?

Current liabilities include invoices, such as supplier payments, short-term debt, or a tax bill, that need to be paid within 12 months. Due to the way the ROCE equation works, having large bills due in the near term can make it look as though a company has less capital employed, and thus a higher ROCE than usual. To check the impact of this, we calculate if a company has high current liabilities relative to its total assets.

Apollo Medical Holdings has total assets of US$552m and current liabilities of US$92m. As a result, its current liabilities are equal to approximately 17% of its total assets. A fairly low level of current liabilities is not influencing the ROCE too much.

Our Take On Apollo Medical Holdings’s ROCE

This is good to see, and with a sound ROCE, Apollo Medical Holdings could be worth a closer look. Of course you might be able to find a better stock than Apollo Medical Holdings. So you may wish to see this free collection of other companies that have grown earnings strongly.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.